drugset / Trial / NCT03325114
Safety and Efficacy of Chlorthalidone in Type 1 Diabetes
Phase 2
Terminated
1 enrolled
University of Rochester
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
NaSingle-groupOpen-labelTreatment
Summary
This open-label study will determine if chlorthalidone is safe and effective for the use of reducing urinary calcium excretion over 4 weeks in subjects with type 1 diabetes
Timeline
- Start
- 2019-06-28
- Primary completion
- 2020-06-01
- Completion
- 2020-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Chlorthalidone | Other / unclassified | — | Oral |